FDA’s Circulatory System Devices Advisory Panel will review Boston Scientific Corp.’s Watchman left atrial appendage closure technology for the third time during an Oct. 8-9 meeting in Gaithersburg, Md., the agency said in an Aug. 25 notice.
On the first day of the meeting, FDA will seek committee review and recommendations regarding new clinical data and associated...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?